ArticlePediatric diabetes2018

Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics.

Gordon C Weir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.